CN109922806A - Hydrobromic acid Vortioxetine long acting injection - Google Patents
Hydrobromic acid Vortioxetine long acting injection Download PDFInfo
- Publication number
- CN109922806A CN109922806A CN201780066679.6A CN201780066679A CN109922806A CN 109922806 A CN109922806 A CN 109922806A CN 201780066679 A CN201780066679 A CN 201780066679A CN 109922806 A CN109922806 A CN 109922806A
- Authority
- CN
- China
- Prior art keywords
- hydrobromic acid
- preparation
- vortioxetine
- suspension
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of hydrobromic acid Vortioxetine long acting injections.The preparation includes hydrobromic acid Vortioxetine, suspending agent, stabilizer, buffer, pH adjusting agent, solvent, the preparation can be the agent of instant liquid injection, it may be freeze drying powder injection, there is obvious slow release effect after the preparation injection, administration number of times can be reduced, extend drug treating time, improve patient compliance, improves bioavilability.Meanwhile the present invention also provides the method for preparing above-mentioned hydrobromic acid Vortioxetine long acting injection, this method simple economy is suitable for industrialized production.
Description
The present invention relates to field of medicine preparations, and in particular to a kind of hydrobromic acid Vortioxetine long acting injection.
Depression is also known as depressive disorder, low for main clinical characteristics with significant and lasting mental state, is the main Types of mood disorder.Clinical visible mental state is low, depression of feeling oneself inferior or even pessimistic and worldweary, there is conamen or behavior.Majority of cases has the tendency that recurrent exerbation, and breaking-out is most of every time to alleviate, and can partially have residual symptoms or switch to chronic.In the whole world, the number influenced by some form of depression accounts for the 25% of whole women, and the 10% of whole males, and all teen-age 5%.The cause of disease of depression is unclear, currently, antidepressants have become the preferred treatment means of depressed patient, clinically based on the suppression agent of selective serotonin (5-HT) reuptake, is most widely used.
Vortioxetine is the new drug of listing in 2013, it is mainly used for the treatment of major depressive disorder (MDD), its mechanism of action is not yet completely clear, but has been generally acknowledged that and extract that inhibitions is related again with 5-HT, is first antidepressants including 5-HT receptor activation and reabsorption inhibition double action mechanism.The medical instrument has safety data that is non-bad or being better than SSRIs (serotonin reuptake inhibitor) and SNRIs (serotonin and norepinephrine reuptake inhibitors), better body weight control data.The excellent effect of patient's Vortioxetine for being unable to complete response to SSRI/SNRI is in agomelatine.It is similar to Duloxetine to treat depression effect, and it is better than Venlafaxine and agomelatine, in addition good security, liver, impaired renal patient crowd are also suitable, effect is better than vilazodone, it should be noted that its risk for increasing youth suicide tendency, but Vortioxetine is better than traditional SSRIs in terms of validity and safety on the whole.Vortioxetine only has the hydrobromic acid Vortioxetine tablet of the oral administration of different size to list at present, the dosage form blood concentration is held time short, need to be administered daily (once a day), due to needing frequent drug administration, increase the not compliance of patient, and due to patient mood swing itself and the influence of other symptoms, difficulty of voluntarily taking medicine is caused, treatment failure is frequently resulted in.
Current there is no the long-acting injections of Vortioxetine and its salt to list, and lacks the research of the non-intestinal drug delivery agent to Vortioxetine and its salt in the prior art.
Summary of the invention
Summary of the invention
First aspect present invention provides a kind of hydrobromic acid Vortioxetine long acting injection, the concentration of hydrobromic acid Vortioxetine is higher in said preparation, size tunable, it can be in limited volume injected, obtain higher dosage, and pass through control particle diameter distribution, have the function that long-acting drug release, said preparation is after injection, the sustained release hydrobromic acid Vortioxetine during at least 2 weeks time, said preparation storage stability is good, it brings new medication to select to the special population that should not be administered orally, and can be administered once within two weeks, increase the compliance of patient.
Second aspect of the present invention provides a kind of preparation method of hydrobromic acid Vortioxetine long acting injection described in first aspect, and this method is simple and easy, and stability is good, it is highly-safe, suitable for industrialized production, this method can also increase freeze-drying step, be prepared into the freeze-drying of hydrobromic acid Vortioxetine
Preparation.
Third aspect present invention provides a kind of hydrobromic acid Vortioxetine long acting injection in preparation for treating the purposes in severe depression disease drug.
Term definition
The invention is intended to cover all replacement, modification and equivalent technical solutions, they are included in the scope of the invention defined such as claim.Those skilled in the art will appreciate that many can be used in the practice present invention with similar or equivalent method and material described herein.The present invention is not limited to method described herein and material.Document, patent and the similar material combined one or more from the application is different or contradicts in the case where (including but not limited to defined in term, term application, described technology etc.), be subject to the application.
It will further be appreciated that certain features of the invention, be it is clearly visible, be described in a number of independent embodiments, but can also provide in combination in a single embodiment.Conversely, various features of the invention are described in a single embodiment for brevity, but can also be individually or with the offer of any suitable sub-portfolio.
Unless otherwise stated, all scientific and technical terminologies used in the present invention, which have, is generally understood identical meaning with those skilled in the art of the invention.All patents of the present invention and public publication are integrally incorporated the present invention by reference.
Term "comprising" or " comprising " are open language, that is, include content specified by the present invention, but otherwise content is not precluded.
In the context of the present invention, wordings such as " about " or " about " whether or not using, all numbers being disclosed are approximation.The numerical value of each number is possible to the reasonable difference that will appear 10% difference below or those skilled in the art think, such as 1%, 2%, 3%, 4% or 5% difference.
Term " D [4,3] " refers to the volumetrically weighted average measured using 2000 laser granulometry of Malvern Mastersizer.
Term " Dv10 " refers to that the cumulative particle sizes volume percentile an of sample reaches partial size corresponding when 10%, term " Dv50 " refers to that the cumulative particle sizes volume percentile an of sample reaches partial size corresponding when 50%, and term " Dv90 " refers to that the cumulative particle sizes volume percentile an of sample reaches partial size corresponding when 90%.
LC/MS/MS refers to LC-MS.
" sustained release " refers to using LC/MS/MS analysis instrument test sample, is limited according to its detection, can detect the blood concentration of hydrobromic acid Vortioxetine.
TPGS refers to that polyethylene glycol 1000 vitamin E succinic acid ester, EL 35 refer to polyoxyethylene (35) castor oil.
Concentration " mg/mL " refers to mg/ml, is weight/volume, and the volume is suspension volume.
μm refer to that micron, μ L refer to microlitre, L refers to liters, and mm refers to millimeter, and mL refers to milliliter, and nm refers to nanometer, and ng refers to nanogram, and kg refers to kilogram, and min refers to minute, and d refers to number of days, and Hz refers to hertz, and g refers to gram that qs., which refers to, to be added to, and mbar refers to that millibar, V refer to volt, DEG C finger degree Celsius.
Detailed description of the invention
Based on the deficiencies of the prior art, the present invention is prepared for the long-acting injection of the drug of Vortioxetine containing hydrobromic acid, is somebody's turn to do by deeply investigating and studying
Preparation can be the form of suspension, be also possible to the form of freeze-dried powder, the former can directly use, the latter is used with matched sterile water for injection mixing preparation at suspension, intramuscular injection or injected s.c. are taken, relative to oral Vortioxetine tablet, invention advantage includes:
(1) hydrobromic acid Vortioxetine exists in the suspension with the low slightly solubility particle of solubility, after injection can slow sustained release drugs, can obviously reduce administration number of times, peak valley avoided to fluctuate, to improve curative compliance and the safety of patient；
(2) this preparation drugloading rate is higher, can get the sustained release of at least 2 weeks or longer time；
(3) hydrobromic acid Vortioxetine granularity is smaller in the suspension, and is evenly distributed, and has good syringeability, is conducive to improve its bioavilability.
The suspension or freeze-dried preparation that the present invention obtains, all have good stability, are conducive to storage and transport.
The present invention provides a kind of hydrobromic acid Vortioxetine ejection preparation, and the preparation drugloading rate is higher, and wherein the concentration range of hydrobromic acid Vortioxetine is 40.0mg/mL-400.0mg/mL.In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 60.0mg/mL-350.0mg/mL.In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 50.0mg/mL-200.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 60.0mg/mL-150.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 150.0mg/mL-200.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 150.0mg/mL-300.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 200.0mg/mL-300.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 50.0mg/mL-300.0mg/mL；In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 300.0mg/mL-350.0mg/mL.In some embodiments, the concentration of the hydrobromic acid Vortioxetine is 63mg/mL, 150.0mg/mL, 190.2mg/mL, 300.0mg/mL or 380.0mg/mL.
The hydrobromic acid Vortioxetine ejection preparation, including stabilizer.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer and suspending agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer and/or suspending agent and/or buffer and/or pH adjusting agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, suspending agent, buffer and pH adjusting agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, buffer and pH adjusting agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, suspending agent and pH adjusting agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, buffer.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, pH adjusting agent.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, including stabilizer, suspending agent, buffer.
The concentration range of the stabilizer is 0.1mg/mL-60.0mg/mL.In some embodiments, the concentration range of the stabilizer is 1.0mg/mL-40.0mg/mL perhaps 0.01mg/mL-20.0mg/mL or 0.1mg/mL-10.0mg/mL, or 5.0mg/mL-55.0mg/mL, perhaps 1.0mg/mL-5.0mg/mL perhaps 5.0mg/mL-10.0mg/mL or 5.0mg/mL-20.0mg/mL, or 5.0mg/mL-40.0mg/mL, perhaps 10.0mg/mL-20.0mg/mL perhaps 10.0mg/mL-40.0mg/mL or 20.0
Mg/mL-40.0mg/mL or 40.0mg/mL-50.0mg/mL.In some embodiments, the concentration range of the stabilizer is 5.0mg/mL-55.0mg/mL.In some embodiments, the concentration of the stabilizer is 4.0mg/mL, 6.0mg/mL, 10.0mg/mL, 18.0mg/mL, 20.0mg/mL, 40.0mg/mL or 50.0mg/mL.In some embodiments, the concentration of the stabilizer is about 53.5mg/mL.
The stabilizer includes at least one selected from polysorbas20, polysorbate60, Tween 80, span 20, PLURONICS F87, polyethylene glycol 1000 vitamin E succinic acid ester, Crodaret RH40, EL 35, lecithin, acid esters polyethylene glycol -15- hydroxy stearic acid ester, polyethylene glycol.In some embodiments, the stabilizer is polysorbas20, Tween 80, the combination of TPGS, EL 35 or polysorbas20 and span 20.
The concentration range of the suspending agent is 0.1mg/mL-20.0mg/mL perhaps 0.1mg/mL-5.0mg/mL perhaps 0.2mg/mL-2.0mg/mL perhaps 0.5mg/mL-5.0mg/mL perhaps 1.0mg/mL-5.0mg/mL or 2.0mg/mL-5.0mg/mL.In some embodiments, the concentration range of the suspending agent is 0.2-2.0mg/mL.In some embodiments, the concentration of the suspending agent is 0.5mg/mL, 1.0mg/mL, or about 0.53mg/mL.In some embodiments, the concentration of the suspending agent is 0.5mg/mL.In some embodiments, the concentration of the suspending agent is 1.0mg/mL.In some embodiments, the concentration of the suspending agent is about 0.53mg/mL.In some embodiments, the concentration of the suspending agent is about 5.0mg/mL.
The suspending agent includes at least one selected from sodium carboxymethylcellulose, gelatin, polyvinylpyrrolidone, methylcellulose, Arabic gum.In some embodiments, the suspending agent is sodium carboxymethylcellulose.The buffer includes at least one selected from sodium dihydrogen phosphate-water, disodium hydrogen phosphate, acetic acid, citric acid, sodium citrate, succinic acid, adipic acid, tartaric acid, ascorbic acid, benzoic acid, malic acid.In some instances, the buffer is sodium dihydrogen phosphate-water.
The pH adjusting agent is selected from acidic ph modifier or alkaline pH adjusting agent, and the acidic ph modifier is selected from at least one of hydrochloric acid, acetic acid, phosphoric acid, and the alkaline pH adjusting agent is selected from at least one of sodium hydroxide, dibastic sodium phosphate, calcium carbonate, magnesium hydroxide.In some embodiments, the pH adjusting agent is sodium hydroxide.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration range 60.0mg/mL-350.0mg/mL,
(b) stabilizer Tween 80,
(c) suspending agent sodium carboxymethylcellulose,
(d) buffer sodium dihydrogen phosphate-water,
It and optionally include pH adjusting agent sodium hydroxide.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 190.2mg/mL,
(b) stabilizer Tween 80, concentration 10.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 0.5mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 190.2mg/mL,
(b) stabilizer Tween 80, concentration 10.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 1.0mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In a specific example, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 150.0mg/mL,
(b) stabilizer Tween 80, concentration 40.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration are about 0.53mg/mL,
(d) buffer sodium dihydrogen phosphate-water,
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 50mg/mL,
(b) stabilizer polysorbas20, concentration 50.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 2.0mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 60mg/mL,
(b) stabilizer EL35, concentration 20.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 0.5mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 300.0mg/mL,
(b) stabilizer T PGS, concentration 5.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 5.0mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 200.0mg/mL,
(b) stabilizer Tween 80, concentration 10.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 0.5mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 200.0mg/mL,
(b) stabilizer polysorbas20, concentration 10.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 0.5mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
In some embodiments, a kind of hydrobromic acid Vortioxetine ejection preparation, comprising:
(a) hydrobromic acid Vortioxetine, concentration 200.0mg/mL,
(b) stabilizer EL35, concentration 10.0mg/mL,
(c) suspending agent sodium carboxymethylcellulose, concentration 0.5mg/mL,
(d) buffer sodium dihydrogen phosphate-water；
It optionally include pH adjusting agent sodium hydroxide, to adjust pH value as 6.0 to 7.0.
The hydrobromic acid Vortioxetine ejection preparation, the wherein D [4 of the hydrobromic acid Vortioxetine, 3] range is 0.05 micron -20.0 microns, or 0.1 micron -10.0 microns, perhaps 1.0 microns -10.0 microns perhaps 0.5 micron -15 microns or 0.1 micron -1.0 microns, perhaps 10.0 microns -15.0 microns or 15.0 microns -20.0 microns.In some embodiments, wherein D [4, the 3] range of the hydrobromic acid Vortioxetine is 1.0 microns -10.0 microns.
Hydrobromic acid Vortioxetine ejection preparation of the present invention, after injection, the sustained release hydrobromic acid Vortioxetine during at least 2 weeks time.
Hydrobromic acid Vortioxetine ejection preparation of the present invention, it can be suspension formation, it is present in the D [4 of the hydrobromic acid Vortioxetine in suspension, 3] range is 0.05 micron -20.0 microns, preparation sustained release hydrobromic acid Vortioxetine during at least 2 weeks time, up to 4 weeks time or the time of such as up to 6 weeks longer time.
Hydrobromic acid Vortioxetine ejection preparation of the present invention, it can be suspension formation, the concentration range for being present in the hydrobromic acid Vortioxetine in suspension is 40.0mg/mL-400.0mg/mL, preparation sustained release hydrobromic acid Vortioxetine during at least 2 weeks time, up to 4 weeks time or the time of such as up to 6 weeks longer time.
Hydrobromic acid Vortioxetine ejection preparation of the present invention can be the agent of instant liquid injection or lyophilized preparation.It is in some embodiments i.e. use
Type liquid injection agent is in some embodiments freeze drying powder injection.
In some embodiments, the hydrobromic acid Vortioxetine ejection preparation is lyophilized preparation, and the lyophilized preparation is the form of cake block.
On the other hand, the present invention provides a kind of method for preparing any of the above-described hydrobromic acid Vortioxetine ejection preparation.A method of preparing hydrobromic acid Vortioxetine ejection preparation, including the following steps:
(a) stabilizer, optional and buffer are successively dissolved in the water respectively,
(b) optionally, suspending agent is added into above-mentioned solution, stirring to being completely dissolved,
(c) hydrobromic acid Vortioxetine is added, obtains suspension, optionally, adjusting pH value with pH adjusting agent is 6.0 to 7.0, constant volume,
(d) by above-mentioned suspension ball mill grinding, final suspension is obtained.
In some embodiments, a method of preparing hydrobromic acid Vortioxetine ejection preparation, including the following steps:
(a) polysorbas20, sodium dihydrogen phosphate-water are successively dissolved in the water respectively,
(b) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring to being completely dissolved,
(c) hydrobromic acid Vortioxetine is added, obtains suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume,
(d) above-mentioned suspension is ground with planetary ball mill, obtains final suspension.
A kind of method preparing hydrobromic acid Vortioxetine ejection preparation of the present invention, using wet milling techniques, grinding bead material is the good zirconium oxide of compatibility.
A method of hydrobromic acid Vortioxetine ejection preparation is prepared, may also include the step of being prepared into lyophilized preparation, described the step of being prepared into lyophilized preparation includes: to be freeze-dried the final suspension.In some embodiments, the freeze-drying includes to -30 DEG C by the cooling final suspension hereinafter, and in the final suspension lower than 0 DEG C of dry cooling；In some embodiments, the final suspension freeze-drying is implemented with three phases:
(l) the pre-freeze stage is included in -45 DEG C of final suspensions of cooling,
(2) preliminary drying stage, in lower than 0 DEG C dry cooling final suspension, and
(3) the redrying stage is being higher than 0 DEG C of dry cooling final suspension, to obtain hydrobromic acid Vortioxetine lyophilized preparation.
The hydrobromic acid Vortioxetine lyophilized preparation, after mixing with water, form the injection of suspension formation, wherein, D [4, the 3] range for being present in the hydrobromic acid Vortioxetine in suspension is 0.05 micron -20.0 microns, after the preparation injection, in at least 2 weeks time, sustained release hydrobromic acid Vortioxetine during up to 4 weeks time or the time of such as up to 6 weeks longer time.
The hydrobromic acid Vortioxetine lyophilized preparation, after mixing with water, form the injection of suspension formation, wherein, the concentration range for being present in the hydrobromic acid Vortioxetine in suspension is 40.0mg/mL-400.0mg/mL, after the preparation injection, at least 2 weeks time, sustained release hydrobromic acid Vortioxetine during up to 4 weeks time or the time of such as up to 6 weeks longer time.
The present invention also provides bromic acid Vortioxetine ejection preparation above-mentioned in preparation for treating the purposes in severe depression disease drug.
A kind of bromic acid Vortioxetine ejection preparation can be injected or be subcutaneously injected through intramuscular for treating the purposes in severe depression disease drug, the drug in preparation.
After Fig. 1 description injects 10 preparation of the embodiment of the present invention (01,02, No. 03 prescription in embodiment 10) in rat body, the mean plasma concentration of Vortioxetine and the figure of time relationship.
Embodiment 1: various concentration hydrobromic acid Vortioxetine suspension preparation
Prescription table:
Preparation process:
(1) polysorbas20, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution, detection level and related substance after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: it is more sticky substantially without mobility after the grinding of 04 sample, do not have syringeability, therefore the prescription is studied without next step.Remaining prescription sample is shown in Table 1-1 and table 1-2.
Hydrobromic acid Vortioxetine grain graininess in suspension after table 1-1 grinding (unit: μm)
Hydrobromic acid Vortioxetine suspension granularity Detection instrument parameter (embodiment is general):
According to experimental result it is found that concentration is the suspension of 63mg/mL and 380mg/mL, it can get D [4,3] after grinding between 1.0-10.0 microns, the suspension syringeability is good.
40 DEG C of study on the stability of table 1-2 suspension
According to experimental result it is found that concentration is the suspension of 63mg/mL and 380mg/mL, process impurity is not introduced into after grinding；And after acceleration environment places 30 (or 35) days, content and related substance do not have significant change.
Hydrobromic acid Vortioxetine content and related substance method (embodiment is general)
Chromatographic condition:
High performance liquid chromatograph (Agilent HPLC-DAD)
Chromatographic column: Symmetryshield RPC18,150mm × 4.6mm, 3.5 μm
Detector: UV detector, Detection wavelength 230nm flow velocity: 1.0ml/min
Mobile phase A: 0.05% trifluoroacetic acid Mobile phase B: acetonitrile
Diluent: water: acetonitrile=80:20 column temperature: 35 DEG C
Related substance gradients elution requirement is as follows, runing time 70min, and sample volume is 20 μ l:
| Time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 80 | 20 |
| 30 | 60 | 40 |
| 50 | 20 | 80 |
| 60 | 20 | 80 |
| 60.1 | 80 | 20 |
| 70 | 80 | 20 |
Concentration gradients elution requirement is as follows, runing time 40min, and sample volume is 10 μ l:
| Time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 80 | 20 |
| 30 | 60 | 40 |
| 30.1 | 80 | 20 |
| 40 | 80 | 20 |
Embodiment 2: different prescription hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) polysorbas20, Tween 80, EL 35, TPGS, sorbester p17 are successively dissolved or dispersed in sodium dihydrogen phosphate-water respectively in the purified water of about 60% preparation total amount；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution, detection level and related substance after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: when using sorbester p17 as stabilizer, a large amount of API are precipitated after grinding, can not obtain stable suspension, therefore the prescription is not suitable for carrying out next step research.Remaining sample result is shown in Table 2-1 and table 2-2.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 2-1 grinding (unit: μm)
Conclusion: concentration is the suspension of 190.2mg/mL, and different prescription (stabilizer) samples after grinding can get the suspension of D [4,3] between 1.0-10.0 microns, after acceleration environment is placed 20 days, partial size is without significant change.
40 DEG C of study on the stability of table 2-2 suspension
Conclusion: concentration is the suspension of 190.2mg/mL, different prescription (stabilizer) samples, stable content after grinding, and is not introduced into process impurity, after 40 DEG C are placed 35 days, does not there is significant change.
Embodiment 3: different prescription hydrobromic acid Vortioxetine lyophilized preparation preparations
Prescription table:
Preparation process:
(1) polysorbas20, Tween 80, EL 35, TPGS, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution, detection level and related substance after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer；
(6) suspension after grinding is filling in 7ml cillin bottle, filling amount 2ml is freeze-dried, and partial size, content, related substance after measurement freeze-drying place acceleration environment, investigate stability, lyophilized technique such as table 3-1:
Table 3-1 lyophilized technique
Experimental result: 3-2 and table 3-3 are shown in Table.
Hydrobromic acid Vortioxetine grain graininess (unit: μm) in each batch suspension of table 3-2 freeze-drying front and back
Conclusion: concentration is the suspension of 190.2mg/mL, and different prescription (stabilizer) samples after grinding can get the suspension of D [4,3] between 1.0-10.0 microns, and front and back granularity is lyophilized without significant change.
Table 3-3 suspension freeze-drying front and back content, the variation of related substance
Conclusion: concentration is the suspension of 190.2mg/mL, and different prescription (stabilizer) samples after freeze-drying, content and related substance are without significant change.
Embodiment 4: different-grain diameter hydrobromic acid Vortioxetine suspension preparation
Prescription table:
Preparation process:
(1) TPGS, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；；
(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: 4-1 and table 4-2 are shown in Table.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 4-1 grinding (unit: μm)
0 day content of table 4-2 suspension and related material result
Conclusion: the suspension of same prescription can prepare the suspension of different D [4,3], and content, related substance meet the requirements by control abrasive parameters (grinding bead proportion and milling time).
Embodiment 5: different Tween-20 dosage hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) polysorbas20, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: it is shown in Table 5-1.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 5-1 grinding (unit: μm)
Conclusion: Tween-20 dosage is that can get the suspension of D [4,3] between 1.0-10.0 microns after grinding within the scope of 6mg/mL to 40mg/mL, and after acceleration environment placement 30 days, partial size is without significant change in prescription.
Embodiment 6: different Tween-80 dosage hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) Tween 80, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: when Tween 80 dosage is 2mg/ml, after grinding, more AP is precipitated, it is difficult to it is prepared into stable suspension, therefore the prescription is studied without next step, remaining batch the results are shown in Table 6-1 and table 6-2.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 6-1 grinding (unit: μm)
Conclusion: Tween-80 dosage is that can get the suspension of D [4,3] between 1.0-10.0 microns after grinding within the scope of 4mg/mL to 40mg/mL, and after acceleration environment placement 30 days, partial size is without significant change in prescription.
Hydrobromic acid Vortioxetine content and related substance in each batch suspension after table 6-2 grinding
Conclusion: Tween-80 dosage is within the scope of 4mg/mL to 40mg/mL in prescription, and the suspension of preparation has good stability, and acceleration environment is put
After setting 30 days, content and related substance do not have significant change.When Tween 80 dosage is 2mg/ml even lower, then stable suspension can not be prepared into.
Embodiment 7: different 35 dosage hydrobromic acid Vortioxetine suspension of EL preparations
Prescription table:
Preparation process:
(1) EL 35, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: when 35 dosage of EL is 2mg/ml, after grinding, more API is precipitated, it is difficult to it is prepared into stable suspension, therefore the prescription is studied without next step, remaining batch the results are shown in Table 7-1.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 7-1 grinding (unit: μm)
Conclusion: EL-35 dosage is that can get the suspension of D [4,3] between 1.0-10.0 microns after grinding within the scope of 4mg/mL to 40mg/mL, and after acceleration environment placement 30 days, partial size is without significant change in prescription.When EL-35 dosage is 2mg/ml even lower, then stable suspension can not be prepared.
Embodiment 8: different TPGS dosage hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) TPGS, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively, are dissolved by heating；
(2) after being cooled to room temperature, the sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: it is shown in Table 8-1.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 8-1 grinding (unit: μm)
Conclusion: TPGS dosage is that can get the suspension of D [4,3] between 1.0-10.0 microns after grinding within the scope of 10mg/mL to 40mg/mL, and after acceleration environment placement 30 days, partial size is without significant change in prescription.
Embodiment 9: hydrobromic acid Vortioxetine long-acting injection is in the intracorporal pharmacokinetic study of rat
Prescription table:
Preparation process:
(1) polysorbas20, TPGS, span 20 sodium dihydrogen phosphate-water successively dissolved respectively, be scattered in the purified water of about 60% preparation total amount；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer.
Experimental result: it is shown in Table 9-1.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 9-1 grinding (unit: μm)
Conclusion: API concentration is the suspension of 190.2mg/mL and 300mg/mL, and different prescription (stabilizer) samples, can get the suspension of D [4,3] between 1.0-10.0 microns after grinding.
Various concentration and prescription sample in selection example 9 carry out rat experiment, test as follows:
The LC/MS/MS system of analysis includes the serial vacuum degassing furnace of Agilent 1200, binary syringe pump, orifice plate automatic sampler, column insulating box, the Agilent G6430 three-level level four bars mass spectrograph in charged spray ionization source (ESI).Quantitative analysis carries out under MRM mode, MRM
The parameter of conversion is as in Table A:
Table A
| More reaction detection scannings | 299.1→150 |
| Fragmentation voltage | 25V |
| Capillary voltage | 4000V |
| Dryer temperature | 350℃ |
| Atomizer | 40psi |
| Drier flow velocity | 9L/min |
Analysis uses Waters Xbridge C18,2.1 × 50mm, 2.7 μM column, injects 15 μ L samples.Analysis condition: mobile phase is+0.1% formic acid (B) of+0.1% formic acid of 2mM ammonium formate (A) and methanol+2mM ammonium formate.Flow velocity is 0.3mL/min.Eluent gradient is as shown in tableb:
Table B
The present invention assesses 01,02, No. 03 sample of embodiment 9 in the intracorporal pharmacokinetic of rat.Using administered intramuscular, after animal gives Vortioxetine mixed suspension preparation (30mg/kg or 47.2mg/kg).Before administration with 0.25h, 1h after administration, 2h, 5h, 7h, for 24 hours, 48h, 72h, 96h, 120h, 144h, 168h, 216h, 288h, 336h, 408h and 504h acquire whole blood, frozen after separated plasma to be measured.And it is centrifuged 2 minutes under 12,000 revs/min.Blood plasma is collected, is saved at -20 DEG C or -70 DEG C until carrying out above-mentioned LC/MS/MS analysis.Table 9-2 lists in embodiment 93 samples in the intracorporal pharmacokinetic data of rat.The compounds of this invention has good pharmacokinetic property, and different sustained release trend is embodied compared with solution.Including ideal peak time (Tmax), half-life period (T1/2) and exposed amount (AUClast), it absorbs and release profiles is more gentle compared with solution, T1/2Between 95-134h, detection limit or more can be maintained substantially in 504h Vortioxetine blood concentration.Averagely Drug-time curve is shown in Figure of description 1 to 9 preparation of the embodiment of the present invention in vivo after rat muscle injection.
Table 9-2: compound is in the intracorporal pharmacokinetic data of rat
Embodiment 10: different sodium carboxymethylcellulose dosage hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) Tween 80, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer, and acceleration environment is placed, investigates stability.
Experimental result: when sodium carboxymethylcellulose dosage is 10mg/ml, after grinding, sample producing bubbles are obvious, and more sticky, which does not have syringeability, therefore the prescription is studied without next step.Remaining prescription the results are shown in Table 10-1.
Hydrobromic acid Vortioxetine grain graininess in each batch suspension after table 10-1 grinding (unit: μm)
Conclusion: carboxymethyl cellulose dosage is that can get the suspension of D [4,3] between 1.0-10.0 microns after grinding within the scope of 0.5mg/mL to 5mg/mL in prescription.When carboxymethyl cellulose dosage is more than 10.0mg/mL, then the suspension of injectable can not be prepared.
Embodiment 11: different suspending agent hydrobromic acid Vortioxetine suspension preparations
Prescription table:
Preparation process:
(1) Tween 80, sodium dihydrogen phosphate-water are successively dissolved in the purified water of about 60% preparation total amount respectively；
(2) sodium carboxymethylcellulose of recipe quantity, hydroxypropyl methylcellulose is added into above-mentioned solution, stirring is to being completely dissolved；
(3) it stirs on one side, is slowly added to the hydrobromic acid Vortioxetine of recipe quantity on one side, stir to obtain Vortioxetine suspension, adjusting pH value with sodium hydroxide is 6.0 to 7.0, constant volume；
(4) above-mentioned suspension is ground with ball mill；
(5) using suspension size distribution after the measurement grinding of 2000 particle size analyzer of Malvern Mastersizer.
Experimental result: when using hydroxypropyl methylcellulose for suspending agent, after grinding, sample producing bubbles are obvious, and without mobility, which does not have syringeability, therefore the prescription is studied without next step.Remaining prescription the results are shown in Table 11-1.
Hydrobromic acid Vortioxetine grain graininess in suspension after table 11-1 grinding (unit: μm)
Conclusion: selecting sodium carboxymethylcellulose for suspending agent, can get the suspension of D [4,3] between 1.0-10.0 microns after grinding.Using hydroxypropyl methylcellulose as suspending agent, then the suspension of injectable can not be prepared.
In the description of description of the invention, the description of reference term " some embodiments ", " some embodiments ", " specific example " or " some examples " etc. means that particular features, structures, materials, or characteristics described in conjunction with this embodiment or example are included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms need not be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more of the embodiments or examples.In addition, without conflicting with each other, the feature of different embodiments or examples described in this specification and different embodiments or examples can be combined by those skilled in the art.
Although the embodiments of the present invention has been shown and described above, it can be understood that, above-described embodiment is exemplary, and is not considered as limiting the invention, and those skilled in the art can make changes, modifications, alterations, and variations to the above described embodiments within the scope of the invention.
Claims (17)
- A kind of hydrobromic acid Vortioxetine ejection preparation, which is characterized in that the concentration range of the hydrobromic acid Vortioxetine is 40.0mg/mL-400.0mg/mL.
- Preparation according to claim 1 further comprises stabilizer.
- Preparation according to claim 2 further comprises optionally suspending agent and/or buffer and/or pH adjusting agent.
- Preparation according to claim 3, the concentration range of the suspending agent are 0.1mg/mL-5mg/mL.
- Preparation according to claim 3, wherein the suspending agent includes at least one selected from sodium carboxymethylcellulose, gelatin, polyvinylpyrrolidone, methylcellulose, Arabic gum.
- Preparation according to claim 2, the concentration range of the stabilizer are 5.0mg/mL-55.0mg/mL.
- Preparation according to claim 2, wherein the stabilizer includes at least one selected from polysorbas20, polysorbate60, Tween 80, span 20, PLURONICS F87, polyethylene glycol 1000 vitamin E succinic acid ester, Crodaret RH40, EL 35, lecithin, acid esters polyethylene glycol -15- hydroxy stearic acid ester, polyethylene glycol.
- Preparation according to claim 3, wherein the buffer includes at least one selected from sodium dihydrogen phosphate-water, disodium hydrogen phosphate, acetic acid, citric acid, sodium citrate, succinic acid, adipic acid, tartaric acid, ascorbic acid, benzoic acid, malic acid.
- Preparation according to claim 3, wherein the pH adjusting agent is selected from acidic ph modifier or alkaline pH adjusting agent, the acidic ph modifier includes at least one selected from hydrochloric acid, acetic acid, phosphoric acid, and the alkaline pH adjusting agent is selected from at least one comprising sodium hydroxide, dibastic sodium phosphate, calcium carbonate, magnesium hydroxide.
- Preparation according to claim 1 comprising:(a) hydrobromic acid Vortioxetine, concentration range 60.0mg/mL-350.0mg/mL,(b) stabilizer Tween 80,(c) suspending agent sodium carboxymethylcellulose,(d) buffer sodium dihydrogen phosphate-water,It and optionally include pH adjusting agent sodium hydroxide.
- Preparation according to claim 1, the D [4,3] of the hydrobromic acid Vortioxetine are 0.05 micron -20.0 microns or 0.1 micron -10.0 microns.
- Preparation according to claim 1, after injection, the sustained release hydrobromic acid Vortioxetine during at least 2 weeks time.
- Preparation according to claim 1 is the agent of instant liquid injection or lyophilized preparation.
- Preparation according to claim 13, wherein the lyophilized preparation is the form of cake block.
- The method for preparing the preparation as described in claim 3-10 is any, including the following steps:(a) by stabilizer, optional and buffer is successively dissolved in the water,(b) optionally, suspending agent is added into above-mentioned solution, stirring to being completely dissolved,(c) hydrobromic acid Vortioxetine is added, obtains suspension, optionally, adjusting pH value with pH adjusting agent is 6.0 to 7.0, constant volume,(d) by above-mentioned suspension ball mill grinding, final suspension is obtained.
- According to the method for claim 15, further include the steps that being prepared into lyophilized preparation, the step includes: to be freeze-dried the final suspension.
- A kind of any preparation of claim 1-14 is preparing the purposes for treating in severe depression disease drug.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016109936425 | 2016-11-09 | ||
| CN201610993642 | 2016-11-09 | ||
| PCT/CN2017/109941 WO2018086534A1 (en) | 2016-11-09 | 2017-11-08 | Vortioxetine hydrobromide long-acting injection preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109922806A true CN109922806A (en) | 2019-06-21 |
| CN109922806B CN109922806B (en) | 2021-11-05 |
Family
ID=62110201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780066679.6A Active CN109922806B (en) | 2016-11-09 | 2017-11-08 | Vortioxetine hydrobromide long-acting injection preparation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109922806B (en) |
| WO (1) | WO2018086534A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114366714A (en) * | 2021-04-29 | 2022-04-19 | 山东京卫制药有限公司 | Agomelatine suspension nasal spray and application thereof |
| CN115052601A (en) * | 2020-03-13 | 2022-09-13 | 广东东阳光药业有限公司 | Composition of piperazine-based drugs |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114222565B (en) * | 2019-10-16 | 2023-10-20 | 广东东阳光药业股份有限公司 | Pharmaceutical composition |
| CN117597111A (en) * | 2021-08-05 | 2024-02-23 | 浙江华海药业股份有限公司 | Vortioxetine pamoate freeze-dried powder injection and preparation method thereof |
| WO2023083212A1 (en) * | 2021-11-10 | 2023-05-19 | 广东东阳光药业有限公司 | Quinoline pharmaceutical composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015035802A1 (en) * | 2013-09-12 | 2015-03-19 | 杭州普晒医药科技有限公司 | Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146953A (en) * | 2014-07-24 | 2014-11-19 | 李雪梅 | Vortioxetine hydrobromide injection |
| US20170196802A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long Acting Injectable Formulations |
| WO2017167180A1 (en) * | 2016-03-29 | 2017-10-05 | 上海华汇拓医药科技有限公司 | Vortioxetine pamoic acid salt and crystal form thereof |
| CN106265498A (en) * | 2016-08-31 | 2017-01-04 | 安徽省润生医药股份有限公司 | A kind of New Hydrogen bromic acid is fertile for western spit of fland injection and preparation method thereof |
| CN107049932B (en) * | 2017-06-22 | 2020-11-06 | 四川大学 | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof |
-
2017
- 2017-11-08 WO PCT/CN2017/109941 patent/WO2018086534A1/en active Application Filing
- 2017-11-08 CN CN201780066679.6A patent/CN109922806B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015035802A1 (en) * | 2013-09-12 | 2015-03-19 | 杭州普晒医药科技有限公司 | Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage |
Non-Patent Citations (1)
| Title |
|---|
| 潘卫三主编: "《工业药剂学》", 31 August 2015, 中国医药科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115052601A (en) * | 2020-03-13 | 2022-09-13 | 广东东阳光药业有限公司 | Composition of piperazine-based drugs |
| CN114366714A (en) * | 2021-04-29 | 2022-04-19 | 山东京卫制药有限公司 | Agomelatine suspension nasal spray and application thereof |
| CN114366714B (en) * | 2021-04-29 | 2022-10-11 | 山东京卫制药有限公司 | Agomelatine suspension nasal spray and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109922806B (en) | 2021-11-05 |
| WO2018086534A1 (en) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109922806A (en) | Hydrobromic acid Vortioxetine long acting injection | |
| Wang et al. | Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study | |
| CN108261394B (en) | Carilazine hydrochloride injection preparation and preparation method and application thereof | |
| US10537524B2 (en) | Apixaban solid composition and preparation method thereof | |
| US8586092B2 (en) | Fulvestrant nanosphere/microsphere and preparative method and use thereof | |
| JP2014512396A (en) | Risperidone sustained release microsphere composition | |
| TW202033193A (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| WO2018108164A1 (en) | Bortezomib pharmaceutical composition and applications thereof | |
| Haupt et al. | Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder | |
| Qi et al. | Thermosensitive hydrogel designed for improving the antidepressant activities of genipin via intranasal delivery | |
| Durairaj et al. | Influence of dosage form on the intravitreal pharmacokinetics of diclofenac | |
| Ma et al. | Design, characterization, and application of a pH-triggered in situ gel for ocular delivery of vinpocetine | |
| WO2018108163A1 (en) | Talazoparib pharmaceutical composition and applications thereof | |
| CN115052601B (en) | Composition of piperazine drugs | |
| Hazekawa et al. | Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion | |
| CN110433131A (en) | A kind of pharmaceutical composition | |
| Zhang et al. | Effect of different absorption enhancers on the nasal absorption of nalmefene hydrochloride | |
| WO2019149159A1 (en) | Composition comprising oxadiazole derivative, preparation method therefor and use thereof | |
| EP3746047B1 (en) | Injectable composition | |
| CN109394709A (en) | A kind of pharmaceutical composition comprising imrecoxib | |
| US20060030556A1 (en) | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency | |
| Nakhla et al. | Injectable long-acting ivacaftor-loaded poly (lactide-co-glycolide) microparticle formulations for the treatment of cystic fibrosis: In vitro characterization and in vivo pharmacokinetics in mice | |
| CN114222565B (en) | Pharmaceutical composition | |
| WO2023083212A1 (en) | Quinoline pharmaceutical composition | |
| WO2014169816A1 (en) | Goserelin sustained release microsphere pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200429 Address after: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1 Applicant after: SUNSHINE LAKE PHARMA Co.,Ltd. Address before: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1 Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. Applicant before: Ruyuan Yongxing Technical Service Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |